Business Wire

Biogen to Present Data at Alzheimer's Association International Conference® 2017 (AAIC®)

Jaa

Biogen (NASDAQ: BIIB) will present data from its Alzheimer’s disease programs at the Alzheimer's Association International Conference® 2017 (AAIC®) in London, July 16 - 20, 2017.

The planned poster presentations include:

  • Change from Baseline in Clinical Dementia Rating Scale Cognitive and Functional Domains in PRIME, a Randomized Phase 1b Study of the Anti-Amyloid Beta Monoclonal Antibody Aducanumab (BIIB037). Poster 1-053: July 16, 2017, 9:30 a.m. GMT+1. This new post-hoc analysis shows the change in the cognitive and functional subscores, which are derived from the previously reported clinical dementia rating (CDR) score for the overall and early Alzheimer’s disease populations in the 1, 3, 6 and 10 mg/kg aducanumab fixed-dosing cohorts in Phase 1b.

    This poster will be available concurrently with the session on the Investors section of the Biogen company website, www.Biogen.com.
  • Signs and Symptoms of Alzheimer’s Disease Noted in Health Records up to 5 Years Prior to Diagnosis . Poster 2-275: July 17, 2017, 9:30 a.m. GMT+1. This analysis reports the documentation of cognitive and behavioral impairment from U.S. medical health records, prior to an Alzheimer’s disease diagnosis.

About Aducanumab

Aducanumab (BIIB037) is an investigational compound being developed for the treatment of early Alzheimer’s disease. Aducanumab is a human recombinant monoclonal antibody (mAb) derived from a de-identified library of B cells collected from healthy elderly subjects with no signs of cognitive impairment or cognitively impaired elderly subjects with unusually slow cognitive decline using Neurimmune’s technology platform called Reverse Translational Medicine (RTM). Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement.

About Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology, and today the company has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook and YouTube.

Biogen Safe Harbor

This press release contains forward-looking statements, including statements relating to the development and potential benefits, safety and efficacy of investigational drugs, including aducanumab and results of certain clinical studies. These statements may be identified by words such as “believe,” “except,” “may,” “plan,” “potential,” “will” and similar expressions, and are based on our current beliefs and expectations. You should not place undue reliance on these statements or the scientific data presented. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. Factors which could cause actual results to differ materially from our current expectations include the risk that we may not fully enroll our clinical trials or enrollment will take longer than expected, unexpected concerns may arise from additional data or analysis, including data, analysis or results obtained during our clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates, or we may encounter other unexpected hurdles which may be impacted by, among other things, the occurrence of adverse safety events, failure to obtain regulatory approvals in certain jurisdictions, failure to protect intellectual property and other proprietary rights, product liability claims, third party collaboration risks, and the other risks and uncertainties that are described in the Risk Factors section of Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and we assume no obligation to update any forward-looking statement.

Contact information

Biogen
MEDIA CONTACT:
Catherine Falcetti, +1 781-464-3260
public.affairs@biogen.com
or
INVESTOR CONTACT:
Matt Calistri, +1 781-464-2442
IR@biogen.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Synteract Announces Collaboration with International Children’s Advisory Network iCAN Research25.6.2018 20:03Tiedote

Synteract, an innovative contract research organization (CRO) providing full, phase I-IV services enabling drug development companies to bring new medicines to market, has signed a memo of understanding to partner with the International Children’s Advisory Network (iCAN). A worldwide consortium of children’s advisory groups, iCAN is dedicated to giving children and families a voice in health, medicine, research, and innovation by increasing education about the importance of children’s involvement. Synteract is a sponsor at the 2018 iCAN Research Summit in Edinburgh, Scotland, UK, July 8-13, 2018 and will hold two interactive plenary seminar sessions at the event. With chapters across the U.S. and worldwide, iCAN partners with local children’s hospitals and addresses the needs of pediatric clinical research and healthcare and advocates for patients worldwide. In partnering with iCAN, Synteract will expand its access to children and families familiar with clinical research. iCAN will sup

GA-ASI to Fly First Trans-Atlantic Flight of a MALE RPA25.6.2018 19:55Tiedote

On July 10-11, General Atomics Aeronautical Systems, Inc. (GA-ASI) plans to make the first-ever trans-Atlantic flight of a Medium-altitude, Long-endurance (MALE) Remotely Piloted Aircraft (RPA). GA-ASI’s company-owned MQ-9B SkyGuardian RPA is scheduled to fly from the company’s Flight Test and Training Center in Grand Forks, North Dakota, USA, to Royal Air Force (RAF) Fairford in Gloucestershire, UK. The aircraft will then be on static display July 13-15 for the Royal International Air Tattoo (RIAT) airshow being held at RAF Fairford. The flight and display will commemorate the RAF’s centenary celebration (RAF100). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005946/en/ GA-ASI’s company-owned MQ-9B SkyGuardian RPA is scheduled to fly from the company’s Flight Test and Training Center in Grand Forks, North Dakota, USA, to Royal Air Force (RAF) Fairford in Gloucestershire, UK. The aircraft will then be on static displa

Quadient Announces General Availability of Quadient Inspire R1225.6.2018 17:30Tiedote

www.quadient.com : Quadient, the award-winning leader in Customer Communications Management (CCM), announced the general availability of its newest release, Quadient Inspire R12, which includes the new Digital Advantage Suite. The updated version of Quadient Inspire is designed to give customers and partners greater control over the systems and processes used to drive consistent communications across all channels with an emphasis on digital experiences. With Inspire R12, users design omni-channel communications in days rather than months with a simple, modern and comprehensive platform. The solution makes it possible to change designs and test for all channels in minutes, with fully integrated tracking and approval processes built in. Additionally, R12 integrates all parts of the communications process from linking journey maps to communications, postal sorting, address, phone and email verifications, email delivery, SMS delivery, mail delivery tracking, and production monitoring to re

The Dementia Discovery Fund Raises $350 Million25.6.2018 16:00Tiedote

The Dementia Discovery Fund (DDF) today announces the completion of its fundraising, with £250 million ($350 million at the time of completion) raised from an influential group of strategic investors committed to developing new medicines for dementia. The goal was met today with a new investment of $60 million from US AARP, the global nonpartisan organisation dedicated to empowering Americans 50 and older to choose how they live as they age. The fundraising far exceeded its initial target of $200 million (£130 million), making it the first and largest venture fund focused entirely on discovering and developing novel therapies for dementia, including Alzheimer’s disease. The DDF makes early stage venture capital investments to develop novel disease-modifying therapeutics for all forms of dementia. The fund is managed by SV Health and was formed through the collaboration of leading pharmaceutical companies (Biogen, Eli Lilly and Company, GSK, Johnson & Johnson, Otsuka (Astex), Pfizer and

Professor Thierry Philip Takes Office as OECI President25.6.2018 15:22Tiedote

Professor Thierry Philip, President of the Institut Curie, has been elected President of the Organisation of European Cancer Institutes ( OECI ) for a three-year term. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005600/en/ Pr Thierry Philip (Photo: Business Wire) At the end of June 2018, Professor Philip, an oncologist and pediatrician, will take over as head of this European organization, which brings together 90 institutes and university centers and whose mission is fully devoted to cancer. This European non-governmental, non-profit organization aims to promote cooperation between its members or associate members and pursues a triple objective: to provide cancer patients in Europe with equal access to high-quality care; to assist European institutes with the implementation of a quality system for oncology care; to promote and accelerate the progress of translational research. In this regard, half of the 90 OECI ce

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes25.6.2018 15:07Tiedote

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomised controlled trials in the EASE phase III programme, investigating the use of empagliflozin in combination with insulin therapy in adults with type 1 diabetes, met their primary endpoint. The primary efficacy endpoint, defined in both trials as placebo-corrected change from baseline in HbA1c after 26 weeks of treatment, was met for all investigated doses of empagliflozin (2.5, 10, and 25 mg). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005579/en/ Type 1 diabetes currently affects approximately 30 million adults worldwide.1 It is an autoimmune disease in which the body does not produce sufficient amounts of insulin and therefore requires life-long daily insulin administration to regulate blood sugar. For some people with type 1 diabetes, it may be challenging to manage blood sugar levels with insulin alone. People with type

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme